Development of a Bioluminescent BRCA1-Deficient Xenograft Model of Disseminated, High-Grade Serous Ovarian Cancer

Yen Ting Shen, Lucy Lu Wang, James Evans, Christine Allen, Micheline Piquette‐MillerInternational Journal of Molecular Sciences 2019 · DOI

TL;DR

Researchers have developed a new bioluminescent animal model that closely mimics human high-grade serous ovarian cancer (HGSOC), particularly in patients with BRCA1/2 deficiencies. This model allows for real-time monitoring of tumor growth and metastasis, and importantly, demonstrates sensitivity to carboplatin, a key chemotherapy drug, making it a valuable tool for testing new ovarian cancer therapies.

What Problem Does This Paper Address?

Translating promising cancer treatments from the lab to the clinic is a major hurdle in cancer research. A key reason for this is the lack of accurate animal models that truly represent human disease. High-grade serous ovarian cancer (HGSOC), the most common and aggressive subtype, presents a particular challenge. Many existing cell lines used in preclinical studies don't accurately reflect the genetic and histological characteristics of HGSOC. Furthermore, a significant portion of ovarian cancer patients (around 50%) have a dysfunctional BRCA1 or BRCA2 gene, which is crucial for DNA repair. However, there's a scarcity of animal models that specifically incorporate this BRCA deficiency, limiting our ability to test therapies tailored to these patients. This paper aims to fill this gap by creating a more representative and clinically relevant animal model for BRCA-deficient HGSOC.

Methods

The researchers utilized the OVCAR8 cell line, which naturally has a hypermethylated BRCA1 promoter, leading to reduced BRCA1 expression. To enable non-invasive monitoring, they stably transfected these cells with a luciferase gene, creating the OVCAR8luc cell line. This allowed for bioluminescent imaging (BLI) to track tumor growth and spread in real-time.

Key techniques employed include:

  • Bioluminescence Imaging (BLI): Used for real-time, in vivo monitoring of tumor burden and progression. This method relies on the enzymatic reaction of luciferin and luciferase to produce light.
  • Xenograft Model Development: OVCAR8luc cells were injected intraperitoneally into immunodeficient mice (NOD/SCID) to establish disseminated tumors.
  • Immunohistochemistry (IHC): Used to confirm the high-grade serous histology of the xenograft tumors by staining for markers like PAX8 and WT1, and to assess hypoxia (HIF-1α).
  • Western Blotting: Employed to assess BRCA1 protein expression in both cell lines and tumor samples.
  • Methylation-Specific Quantitative PCR (qPCR): Used to quantify the methylation status of the BRCA1 promoter region, confirming the mechanism of BRCA1 deficiency.
  • Chemotherapy Efficacy Study: Carboplatin was administered intraperitoneally to assess the model's response to platinum-based therapy.

Datasets

Not discussed in the paper. The study primarily uses established cell lines and generates data from animal experiments.

Key Insights and Ideas

  • BRCA Deficiency is Key: The study highlights the critical role of BRCA1/2 dysfunction in HGSOC and the need for models that capture this genetic vulnerability. BRCAness, a phenotype mimicking BRCA deficiency, is common and impacts treatment response.
  • OVCAR8luc as a Promising Model: The OVCAR8luc xenograft model successfully recapitulates key features of human HGSOC, including peritoneal metastasis, ascites formation, and high-grade serous histology.
  • BLI for Real-Time Monitoring: Bioluminescence imaging proves to be a powerful tool for non-invasively tracking tumor growth and spread, allowing for continuous monitoring without sacrificing animals.
  • BRCA Deficiency Maintained In Vivo: The study demonstrates that the BRCA1 deficiency, driven by promoter hypermethylation, is maintained in the xenograft tumors, making it a stable model for studying BRCA-deficient cancers.
  • Platinum Sensitivity: The model exhibits sensitivity to carboplatin, a standard chemotherapy for ovarian cancer, validating its utility for evaluating therapeutic efficacy.

Key Results

  • Disseminated Disease: The OVCAR8luc xenograft model consistently developed disseminated disease, with tumor nodules found throughout the peritoneal cavity, mimicking the clinical presentation of advanced HGSOC.
  • Histological Validation: Immunohistochemical staining confirmed that the xenograft tumors possessed the characteristic high-grade serous histology, expressing markers like PAX8 and WT1.
  • BRCA1 Deficiency Confirmed: Western blot analysis showed reduced BRCA1 protein expression in OVCAR8luc cells and xenografts compared to BRCA-proficient HEYA8 cells. Methylation-specific qPCR revealed over 80% methylation of the BRCA1 promoter in tumor samples, confirming persistent BRCA1 deficiency.
  • Correlation of BLI and Tumor Weight: A moderate to strong correlation (R² = 0.60 for the 5 million cell group) was observed between bioluminescent signal and tumor weight, indicating BLI is a reliable measure of tumor burden.
  • Carboplatin Efficacy: Intraperitoneal administration of carboplatin significantly reduced tumor growth, as measured by BLI, demonstrating the model's responsiveness to platinum-based chemotherapy.

Limitations and Future Work

  • Ascites Impact on BLI Correlation: The authors note that the development of ascites at later stages of disease can attenuate the bioluminescence signal, leading to a lower correlation between BLI and tumor weight in some instances. They suggest initiating treatment at lower tumor burdens to mitigate this.
  • Model for Early-Stage Disease: While the model is valid for early-stage disease, caution is advised when interpreting BLI data after ascites onset.
  • Future Directions: The paper suggests that this model is well-suited for evaluating the efficacy of novel therapeutics targeting BRCA-deficient HGSOC. Its ability to mimic disseminated disease and BRCA deficiency makes it a valuable preclinical tool for drug development. Further studies could explore its use in combination therapies or for investigating resistance mechanisms.

Summary updated

Abstract

Successful translation of preclinical data relies on valid and comprehensive animal models. While high-grade serous ovarian cancer (HGSOC) is the most prevalent subtype, the most commonly used ovarian cancer cell lines are not representative of HGSOC. In addition, 50% of ovarian cancer patients present with dysfunctional <i>BRCA1/2</i>, however currently there is a shortage of BRCA-deficient models. By utilizing the OVCAR8 cell line, which contains a hypermethylated <i>BRCA1</i> promoter, the aim of the current study was to establish and characterize an animal model for BRCA-deficient HGSOC. Transfection of the luciferase gene to OVCAR8 cells enabled bioluminescent imaging for real-time, non-invasive monitoring of tumor growth. The resulting model was characterized by peritoneal metastasis and ascites formation at late stages of disease. Immunohistochemical staining revealed high-grade serous histology in all resected tumor nodules. Immunoblotting and qPCR analysis demonstrated BRCA1 deficiency was maintained in vivo. Moderate to strong correlations were observed between bioluminescent signal and tumor weight. Lastly, intraperitoneal administration of carboplatin significantly reduced tumor growth as measured by bioluminescence. The current model demonstrated BRCA1 deficiency and a high resemblance of the clinical features of HGSOC. This model may be well-suited for evaluation of therapeutic efficacy in BRCA-deficient HGSOC.
BibTeX
@article{shen2019development,
  author = {Yen Ting Shen and Lucy Lu Wang and James Evans and Christine Allen and Micheline Piquette‐Miller},
  title = {{Development of a Bioluminescent BRCA1-Deficient Xenograft Model of Disseminated, High-Grade Serous Ovarian Cancer}},
  journal = {International Journal of Molecular Sciences},
  year = {2019},
  doi = {10.3390/ijms20102498},
}
Figure